Defiance Daily Target 2X Short PLTR ETF

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

PLTR

PLTW

PLTG

PLTZ

PLTU

PLTD

PTIR

Palantir reported record U.S. growth with government revenue reaching $687 million in Q1 2026, an 84% increase year-over-year, prompting a full-year growth guidance boost to 71%. However, the company faces challenges in Europe as Germany's intelligence agency chose ChapsVision's ArgonOS, limiting its market presence. Analysts express a mixed outlook, noting potential as an AI operating system standard but cautioning against high valuations and dependence on government contracts.

- Palantir’s U.S. government revenue reached $687 million in Q1 2026, marking an 84% year-over-year increase, prompting management to raise full-year growth guidance to 71%.  
- The company faced a setback in Europe as Germany's intelligence agency chose ChapsVision over Palantir, citing data sovereignty issues.  
- While analysts recognize Palantir's potential to become a standard in AI operating systems, concerns about high valuation, slow international growth, and dependence on government contracts persist.

Palantir Tech

Roundhill PLTR WeeklyPay ETF

Leverage Shares 2X Long PLTR Daily ETF

Direxion Daily PLTR Bull 2X Shares

Direxion Daily PLTR Bear 1X Shares

GraniteShares 2x Long PLTR Daily ETF

Palantir posts record growth but faces European market loss

PLOO

Top investor Danny Vena believes Palantir Technologies (NASDAQ:PLTR) is a buy due to its strong growth trajectory, with Q1 2026 showing 85% year-over-year revenue growth. Despite concerns over its premium valuation, Vena highlights a favorable PEG ratio of ~0.52, suggesting the stock is undervalued. Wall Street consensus rates PLTR as a Moderate Buy, with a 12-month price target indicating a potential 40% upside.

- Palantir Technologies is experiencing strong revenue and profit growth, with Q1 2026 showing 85% year-over-year sales growth of $1.63 billion.  
- Despite concerns over its valuation, investor Danny Vena suggests that the company's robust growth potential and a PEG ratio of around 0.52 indicate it is still a buy.  
- The consensus on Wall Street is a Moderate Buy, reflecting 13 Buys, 4 Holds, and 2 Sells, with a 12-month average price target suggesting a potential upside of nearly 40%.

Tip Ranks

Leverage Shares 2x Cpd Acclrtd PLTRMnETF

Defiance Leveraged Long +Income PLTR ETF

'It's All About the Math,' Says Top Investor About Palantir Stock

IDGT

CLOU

XDAT

Ignore the Post-Earnings Selloff in Palantir Stock: The AI Revolution Is Just in the ‘Third Inning’

Barchart Option

iShares US Digital Infrastructure and Real Estate ETF

Global X Cloud Computing ETF

Global X Data Center & Dgtl Infrs ETF

SPDR S&P Software

Proshares Big Data Refiners ETF

Pacer Data & Infrastructure Real Estate ETF

ISHRS S&P Glb It

iShares Expanded Tech Software Sector ETF

Franklin Exponential Data ETF

Ignore the Post-Earnings Selloff in Palantir Stock: The AI Revolution Is Just in the ‘Third Inning’

Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.

Where could Palantir be in 10 years? The bull and bear cases.

Palantir, a US technology firm, is facing criticism in the UK for its involvement in the NHS, with concerns over privacy and surveillance. Critics, including prominent figures and the British Medical Journal, argue that its data handling undermines NHS values. Despite this, Palantir claims to improve healthcare efficiency, with over 120 trusts using its platform. The debate centers on whether Palantir's technology is a solution to bureaucratic issues or a threat to civil liberties and trust in public institutions.

- Palantir, a US technology company, is facing criticism for its data handling and ties to military operations while also promising improvements to public services, particularly the NHS, where it has secured significant contracts.  
- Critics argue that its involvement undermines privacy and threatens the traditional patient-doctor relationship by centralizing health records, shifting control from GPs to the state.  
- Despite concerns, supporters highlight the efficiency gains from Palantir's technology, suggesting it could address longstanding bureaucratic challenges in the UK's health system.

The telegraph

Machiavellian spy firm or NHS saviour? The US giant love-bombing Britain

Palantir shares are down in 2026 after huge gains over the past three years.

NASDAQ Composite Index

This tech stock has outperformed the Nasdaq 3 years running, but is down 25% in 2026. Is now the time to buy?

AG2R LA Mondiale Gestion D Actifs increased its stake in Palantir Technologies Inc. by 13.3% in Q4, acquiring an additional 10,580 shares, bringing its total to 90,294 shares valued at $16,050,000. Other institutional investors, including Vanguard and State Street, also raised their stakes. Analysts have mixed ratings on Palantir, with a consensus target price of $194.68. Recent insider sales were reported, with significant shares sold by executives. Insiders own 9.53% of the company.

- AG2R LA Mondiale Gestion D Actifs increased its stake in Palantir Technologies by 13.3%, holding 90,294 shares valued at $16,050,000.  
- Other institutional investors, including Vanguard and State Street, have also expanded their stakes in the company significantly.  
- Palantir's recent earnings report showed revenue growth of 84.7% year-over-year, with analysts projecting an earnings per share of 1.18 for the current fiscal year.

Market Beat

AG2R LA Mondiale Gestion D Actifs Buys 10,580 Shares of Palantir Technologies Inc. $PLTR

Convergence Investment Partners LLC reduced its stake in Palantir Technologies Inc. (NASDAQ:PLTR) by 89.9% in Q4, selling 15,525 shares and retaining 1,751 shares valued at $311,000. Other hedge funds also adjusted their holdings, with some increasing their stakes significantly. Insider trading activity included sales by Ryan D. Taylor and David A. Glazer, totaling over $5 million. Despite mixed sentiments, analysts remain optimistic about Palantir's growth potential in AI and government software.

- Convergence Investment Partners LLC reduced its stake in Palantir Technologies Inc. by 89.9% during the fourth quarter, holding 1,751 shares valued at $311,000 by the quarter's end.  
- Other hedge funds like Bare Financial Services and Clayton Financial Group increased their stakes, highlighting ongoing interest in Palantir despite recent insider selling.  
- Palantir's stock is currently rated as a Moderate Buy, with a consensus target price of $195.16 amidst mixed market sentiments and strong quarterly performance reporting.

Ondas

Convergence Investment Partners LLC Sells 15,525 Shares of Palantir Technologies Inc. $PLTR

Allegiance Financial Group Advisory Services LLC increased its stake in Palantir Technologies Inc. by 104.7% in Q4, owning 7,448 shares valued at $1.32 million. Other institutional investors also adjusted their holdings. Analyst ratings for Palantir include one Strong Buy, seventeen Buy, eleven Hold, and two Sell, with an average target price of $194.68. Recent insider sales included significant transactions by Ryan D. Taylor and Shyam Sankar, reducing their ownership. Palantir's stock is currently down 1.6%.

- Allegiance Financial Group Advisory Services LLC increased its stake in Palantir Technologies by 104.7%, owning 7,448 shares worth $1,324,000.  
- Palantir reported an 84.7% revenue increase year-over-year, with Q1 earnings of $0.33 per share, exceeding estimates.  
- Insider selling and mixed analyst ratings contribute to a volatile sentiment surrounding the stock, which currently has a target price averaging $194.68.

Allegiance Financial Group Advisory Services LLC Increases Stake in Palantir Technologies Inc. $PLTR

Jefferies channels Michael Burry in unveiling a new call to dump Palantir stock

Defiance Daily Target 2X Short PLTR ETF(PLTZ.US)

Palantir posts record growth but faces European market loss

'It's All About the Math,' Says Top Investor About Palantir Stock

Ignore the Post-Earnings Selloff in Palantir Stock: The AI Revolution Is Just in the ‘Third Inning’

Where could Palantir be in 10 years? The bull and bear cases.

Machiavellian spy firm or NHS saviour? The US giant love-bombing Britain

This tech stock has outperformed the Nasdaq 3 years running, but is down 25% in 2026. Is now the time to buy?

AG2R LA Mondiale Gestion D Actifs Buys 10,580 Shares of Palantir Technologies Inc. $PLTR

Convergence Investment Partners LLC Sells 15,525 Shares of Palantir Technologies Inc. $PLTR

Allegiance Financial Group Advisory Services LLC Increases Stake in Palantir Technologies Inc. $PLTR

Jefferies channels Michael Burry in unveiling a new call to dump Palantir stock